Drugs / MK-6213
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00687271 | Jun 2008 → Jan 2009 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-6213 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00687271 ↗ |
| Route | Oral | “MK-6213 160-mg tablet co-administered orally” NCT00687271 ↗ |